A study on systemic symptoms in patients with pollen allergy

Watanabe Yoshihiro0 sites400 target enrollmentMay 10, 2021

Overview

No summary available.

Registry

who.int

Start Date

May 10, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Watanabe Yoshihiro

•1\. Written informed consent must be obtained before any assessment is performed
•2\. 12 years or older
•3\. Mentally competent and able to communicate verbally
•4\. Agree to provide informed consent (need assent if those are \< 20 years old)
•5\. Consent to conduct diary during the study period
•6\. No plan to relocate to the other part of Japan (except for the neighboring prefecture) during the study period
•7\. Fulfill one of the following criteria for each group:
•(1\) For the systemic symptom group: sensitized to pollen (specific IgE \>\= 0\.70 Ua/mL\* by ImmunoCAP) and;
•a) have suffered from systemic symptoms (e.g., skin symptoms, gastrointestinal symptoms, headache, dizziness, fever, and palpitation) of pollen allergy OR
•b) have IgE\-dependent food allergy caused by fruit, vegetable or soybean

•1\. Patients with a history of biologics use for immune disorders within one year prior to enrollment (biologic for asthma is allowed)
•2\. Patients with chronic respiratory diseases other than asthma, heart/renal diseases, autoimmune diseases requiring medication, inflammatory bowel disease, or malignant tumors
•3\. Patients with multiple chemical sensitivity defined by QEESI questionnaire Q1 \>\= 40 and Q3 \>\= 40
•4\. Other patients judged to be inappropriate